Menu
Durham - North Carolina, USA, September 24th, 2018: SOPHiA GENETICS, leader in Data-Driven Medicine, today announced from the Personalized Medicine World Congress (PMWC) at Duke University that the company has opened operations in Boston to meet the burgeoning demand across the United States.
SOPHiA AI (SOPHiA) is the most widely used technology for genomic analysis, adopted by hundreds of university hospitals worldwide. SOPHiA has already analyzed over 250,000 genomic profiles – currently one every five minutes! Utilized in the context of hereditary disorders and cancer, SOPHiA enables clinicians to accurately detect and characterize genomic alterations. Through the company’s platform, experts can unite across borders and use their shared knowledge to efficiently deliver faster outcomes.
In the United States, SOPHiA GENETICS is already supporting more than 100 university hospitals and is rapidly expanding across the region. The company’s impact has long been recognized overseas as the global forerunner in Data-Driven Medicine. SOPHiA GENETICS is currently ranked as one of the 50 smartest companies in the world by the MIT Tech Review.
Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, commented: “We are experiencing a wide and fast adoption of our technology in North America and are very happy to open our U.S. headquarters in Boston and strengthen our team to support customers’ needs. We currently have 20 people working in the U.S. and we will be expanding to 50 within a year’s time.”
Lars Steinmetz, co-founder of SOPHiA GENETICS and professor at Stanford University added: “When we created SOPHiA GENETICS, we never expected to have such an impact worldwide. Thanks to the expertise and quality delivered by SOPHiA’s dedicated team of experts and its standardized technology SOPHiA, the company has earned the trust of the global genomics community, which is so important to truly accelerate the democratization of Data-Driven Medicine.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
